In contrast, siRNA silencing of CD44-encoding genes in CD44+CD24low/− cells enhanced sensitivity to doxorubicin, suggesting CD44 as a suitable target for treating cancer via gene therapy [30]. The gene discussed is CD44; the disease is cancer.